Neuroprotection & stroke

The strongest clinical signal, and its limits

If Semax has a flagship clinical use, it is ischemic stroke: the acute period of ischemic stroke is the single registered indication of its stronger 1% Russian product. Russian trials from 1997 to 2018 report neurological benefit, and a deep preclinical literature describes how it might protect brain tissue from injury.

This unit walks the ischemic cascade, reviews the human trials and their quality honestly, places them on the evidence hierarchy, and explains the protective mechanisms while keeping the Western-standard gap in clear view.